Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1984 Oct;50(4):509–517. doi: 10.1038/bjc.1984.208

Chemopotentiation in vivo: no loss of sensitization with fractionation.

S A Hill, D W Siemann
PMCID: PMC1976902  PMID: 6487517

Abstract

The response of KHT sarcomas to one, two, five or ten daily fractions of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU), with and without misonidazole (MISO), was evaluated using delay of tumour regrowth as the measure of response. When CCNU was given as 2 dose fractions separated by 24 h rather than as a single treatment, no extra dose was necessary to achieve a particular level of damage, suggesting a lack of damage repair. With increasing fraction number, however, an increasing total dose of drug was required to achieve a given effect, presumably to compensate for proliferation. Increasing drug doses also were readily tolerated (almost twice the LD50/7 for a single dose of CCNU resulted in no deaths when given in a 10 fraction treatment) indicating a large sparing of normal tissue toxicity when CCNU treatments were fractionated. The addition of MISO enhanced the tumour response to CCNU in all treatment schemes. When single doses of CCNU were combined with 0.5 mg g-1 MISO, an enhancement ratio (ER) of approximately 1.5 was observed. This ER was maintained for all fractionated treatment schedules including the 10 daily fraction protocol. In addition, no loss of sensitization with increasing fractionation was observed when a lower dose of 0.2 mg g-1 MISO was combined with each of 5 or 10 daily fractions of CCNU. Similar experiments were performed to test the combination of cyclophosphamide (Cy) and MISO (0.5 mg g-1) in the RIF-1 tumour; again chemopotentiation was maintained with increasing fractionation. These results of combined MISO and fractionated chemotherapy are in contrast to the rapid loss of sensitization observed when MISO is used as a radiation sensitizer and combined with small doses of X-rays, thus providing in vivo evidence of the mechanistic difference between the effects of MISO used as a radiation sensitizer or chemopotentiator. Peripheral white blood cell counts performed on mice receiving 5 daily fractions of CCNU +/- MISO displayed no significant enhancement of normal tissue toxicity by MISO. Thus combining MISO with repeated low dose treatments of a chemotherapeutic agent results in a therapeutic gain.

Full text

PDF
509

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brown J. M. The mechanisms of cytotoxicity and chemosensitization by misonidazole and other nitroimidazoles. Int J Radiat Oncol Biol Phys. 1982 Mar-Apr;8(3-4):675–682. doi: 10.1016/0360-3016(82)90711-8. [DOI] [PubMed] [Google Scholar]
  2. Denekamp J., Stewart F. A. Sensitization of mouse tumours using fractionated X-irradiation. Br J Cancer Suppl. 1978 Jun;3:259–263. [PMC free article] [PubMed] [Google Scholar]
  3. Hill R. P., Bush R. S. Dose fractionation studies with a murine sarcoma under conditions of air or carbogen (95% O2 + 5% CO2) breathing. Int J Radiat Oncol Biol Phys. 1977 Sep-Oct;2(9-10):913–919. doi: 10.1016/0360-3016(77)90189-4. [DOI] [PubMed] [Google Scholar]
  4. Hill R. P., Bush R. S. The effect of misonidazole in combination with radiation dose fractionation. Br J Cancer Suppl. 1978 Jun;3:255–258. [PMC free article] [PubMed] [Google Scholar]
  5. Hinchliffe M., McNally N. J., Stratford M. R. The effect of radiosensitizers on the pharmacokinetics of melphalan and cyclophosphamide in the mouse. Br J Cancer. 1983 Sep;48(3):375–383. doi: 10.1038/bjc.1983.202. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Hirst D. G., Brown J. M., Hazlehurst J. L. Enhancement of CCNU cytotoxicity by misonidazole: possible therapeutic gain. Br J Cancer. 1982 Jul;46(1):109–116. doi: 10.1038/bjc.1982.172. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Kallman R. F., Silini G., Van Putten L. M. Factors influencing the quantitative estimation of the in vivo survival of cells from solid tumors. J Natl Cancer Inst. 1967 Sep;39(3):539–549. [PubMed] [Google Scholar]
  8. Law M. P., Hirst D. G., Brown J. M. Enhancing effect of misonidazole on the response of the RIF-1 tumour to cyclophosphamide. Br J Cancer. 1981 Aug;44(2):208–218. doi: 10.1038/bjc.1981.172. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Lee F. Y., Workman P. Modification of CCNU pharmacokinetics by misonidazole--a major mechanism of chemosensitization in mice. Br J Cancer. 1983 May;47(5):659–669. doi: 10.1038/bjc.1983.104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. McNally N. J. Enhancement of chemotherapy agents. Int J Radiat Oncol Biol Phys. 1982 Mar-Apr;8(3-4):593–598. doi: 10.1016/0360-3016(82)90691-5. [DOI] [PubMed] [Google Scholar]
  11. McNally N. J., Stephens T. C., Twentyman P. R., Hinchliffe M., Peacock J. H., Spooner D. The effect of cytotoxic drugs with or without misonidazole on leucopenia in three strains of mice. Int J Radiat Oncol Biol Phys. 1982 Mar-Apr;8(3-4):659–662. doi: 10.1016/0360-3016(82)90707-6. [DOI] [PubMed] [Google Scholar]
  12. Millar B. C. Hypoxic cell radiosensitizers as potential adjuvants to conventional chemotherapy for the treatment of cancer. Biochem Pharmacol. 1982 Aug 1;31(15):2439–2445. doi: 10.1016/0006-2952(82)90051-x. [DOI] [PubMed] [Google Scholar]
  13. Mulcahy R. T., Siemann D. W., Sutherland R. M. Nitrosourea-misonidazole combination chemotherapy: effect on KHT sarcomas, marrow stem cells and gut. Br J Cancer. 1982 Jun;45(6):835–842. doi: 10.1038/bjc.1982.135. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Palcic B., Brosing J. W., Skarsgard L. D. Survival measurements at low doses: oxygen enhancement ratio. Br J Cancer. 1982 Dec;46(6):980–984. doi: 10.1038/bjc.1982.312. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Roizin-Towle L. A., Hall E. J. Enhanced cytotoxicity of antineoplastic agents following prolonged exposure to misonidazole. Br J Cancer. 1981 Aug;44(2):201–207. doi: 10.1038/bjc.1981.171. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Siemann D. W., Hill R. P., Bush R. S. The importance of the pre-irradiation breathing times of oxygen and carbogen (5% CO2: 95% O2) on the in vivo radiation response of a murine sarcoma. Int J Radiat Oncol Biol Phys. 1977 Sep-Oct;2(9-10):903–911. doi: 10.1016/0360-3016(77)90188-2. [DOI] [PubMed] [Google Scholar]
  17. Siemann D. W. In vivo combination of misonidazole and the chemotherapeutic agent CCNU. Br J Cancer. 1981 Mar;43(3):367–377. doi: 10.1038/bjc.1981.57. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Siemann D. W. Potentiation of chemotherapy by hypoxic cell radiation sensitizers--a review. Int J Radiat Oncol Biol Phys. 1982 Jun;8(6):1029–1034. doi: 10.1016/0360-3016(82)90172-9. [DOI] [PubMed] [Google Scholar]
  19. Siemann D. W. Response of murine tumours to combinations of CCNU with misonidazole and other radiation sensitizers. Br J Cancer. 1982 Feb;45(2):272–281. doi: 10.1038/bjc.1982.43. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Siemann D. W., Sutherland R. M. In vivo tumor response to single and multiple exposures of adriamycin. Eur J Cancer. 1980 Nov;16(11):1433–1440. doi: 10.1016/0014-2964(80)90052-3. [DOI] [PubMed] [Google Scholar]
  21. Siemann D. W., Wolf K., Morrissey S., Wheeler K. T. In vitro potentiation of BCNU activity in rat brain tumour cells pretreated with misonidazole. Br J Cancer. 1984 Jun;49(6):795–799. doi: 10.1038/bjc.1984.123. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Stratford I. J., Adams G. E., Horsman M. R., Kandaiya S., Rajaratnam S., Smith E., Williamson C. The interaction of misonidazole with radiation, chemotherapeutic agents, or heat: a preliminary report. Cancer Clin Trials. 1980 Fall;3(3):231–236. [PubMed] [Google Scholar]
  23. Thomson J. E., Rauth A. M. An in vitro assay to measure the viability of KHT tumor cells not previously exposed to culture conditions. Radiat Res. 1974 May;58(2):262–276. [PubMed] [Google Scholar]
  24. Twentyman P. R., Brown J. M., Gray J. W., Franko A. J., Scoles M. A., Kallman R. F. A new mouse tumor model system (RIF-1) for comparison of end-point studies. J Natl Cancer Inst. 1980 Mar;64(3):595–604. [PubMed] [Google Scholar]
  25. Twentyman P. R. Modification of tumour and host response to cyclophosphamide by misonidazole and by WR 2721. Br J Cancer. 1981 Jun;43(6):745–755. doi: 10.1038/bjc.1981.112. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Wheeler K. T., Wallen C. A., Wolf K. L., Siemann D. W. Hypoxic cells and in situ chemopotentiation of the nitrosoureas by misonidazole. Br J Cancer. 1984 Jun;49(6):787–793. doi: 10.1038/bjc.1984.122. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES